Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to creep in: HTS and UHTS have not lived up to their hype. R&D productivity is not improving, in fact it may be declining.
In the past decade, a handful of scientists and developing companies kept up the cry: “Quality is more important than quantity.” This wisdom is now widely recognized. Customers want better compounds, information-rich assays, effective prediction tools, and to understand how compound structure affects properties.
This is a significant paradigm shift, which will have a profound effect on how drug discovery is done in the future. There will be a lot of interest in new products that promise to provide better information sooner. The goal over the next 10 years will be to turn the existing 70% compound failure rate into a 70% success rate.
This report starts by revisiting some of the “facts” about early discovery phases as they were viewed, and discusses how and why viewpoints have changed. Projections are made about how these changes will play out through 2008. The markets sections of the report include the four major product areas of early discovery:
Market size and growth, leading products and suppliers, market drivers are all be discussed. The report concludes with profiles of 30 key suppliers.
The report is targeted at suppliers of tools and products for early-phase discovery, particularly in the areas of primary screening and combinatorial chemistry. It is designed to provide an understanding of where these phases of drug discovery are headed, what key customers are looking for, the nature of their market segment, and what opportunities exist for new and different products.